Trials are studying the bi-specific targeting of CD3 in combination with the tumor antigen, CEA, which is highly expressed in gastrointestinal malignances, non-small cell lung cancer (NSCLC), breast cancer, uterine, and bladder cancers [NCT02324257], [NCT01284231] (No Title. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.